EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway
Xinyue Zhao, Jiaxi Liu, Dongdong Jin, Chenchen Ren, Li Yang, Yuanhang Zhu, Changhao Huang, Leilei Ding, Zimeng Wu, Ke Shen, Zhen’an Zhang, Huanhuan Chen, Nannan Wang
Journal:Journal of Oncology
IF:4.5
DOI:10.1155/2022/4886907
PMID:36478746
Published:2022-11-28
research field:肿瘤学分子生物学癌症生物学免疫学基因组学
Abstract
Erythropoietin-producing hepatoma receptor A2 (EphA2), receptor tyrosine kinase, the most widespread member of the largest receptor tyrosine kinase family, plays a critical role in physiological and pathological conditions. In recent years, the role of EphA2 in the occurrence and development of cancer has become a research hotspot and is considered a promising potential target. Our previous studies have shown that EphA2 has an indisputable cancer-promoting role in cervical cancer, but its related mechanism requires further research. In this study, high-throughput sequencing was performed on EphA2 knockdown cervical cancer cells and the control group. An analysis of differentially expressed genes revealed that EphA2 may exert its cancer-promoting effect through C-X-C motif chemokine ligand 11 (CXCL11). In addition, we found that EphA2 could further regulate programmed cell death ligand 1 (PD-L1) through CXCL11. This has also been further demonstrated in in vivo experiments. Our study demonstrated that EphA2 plays a tumor-promoting role in cervical carcinoma through the CXCL11/PD-L1 pathway, providing new guidance for the targeted therapy and combination therapy of cervical carcinoma.
本文使用的Yeasen产品


